Deutsche Bank Reiterates Buy, $129 PT On Biogen Idec

In a note out today, Deutsche Bank reiterated a buy rating and $129 price target on biotech firm Biogen Idec BIIB. The price target implies decent upside from current levels. "We continue to see Biogen's BG-12 & Novartis' Gilenya as having more competitive profiles in terms of oral products for MS," Deutsche Bank said in the note.